Please provide your email address to receive an email when new articles are posted on . The cost of palivizumab varies across the world. The antibody was cost-effective in Canada, Colombia, Italy and ...

For infants less than 8 months of age born during or entering their first RSV season and not otherwise protected through maternal vaccination, nirsevimab is considered the first-line recommended ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. Credit: hxyume via Getty ...

Respiratory syncytial virus (RSV) is a major cause of illness in young children and is the leading reason why infants are hospitalized. Until recently, this viral infection was difficult to prevent or ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

The "SYNAGIS Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The report on the global SYNAGIS market presents an all-encompassing analysis ...

Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory studies prevented the virus from developing drug resistance—a persistent ...

As RSV season approaches, some doses of nirsevimab—the monoclonal antibody RSV immunization for infants—are in a limited supply, so the CDC recommends prioritizing doses for high risk infants and ...

There are shortages of an RSV vaccine for infants due to supply issues. The Centers for Disease Control and Prevention (CDC) released a notice last week citing "limited availability" of the ...

A new monoclonal antibody product to protect against respiratory syncytial virus was 90% effective at preventing little children from being hospitalized with RSV, according to new data from the first ...